A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs GSK 1521498 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 29 Aug 2009 Actual end date (Aug 2009) and actual patient number (56) added as reported by ClinicalTrials.gov.
- 29 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2009 New trial record